^™middle.

Gathering signals...

Opthea (ASX:OPT) — Material Events

ASX:OPT · 5 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

4

Opthea’s $340M Profit Fuels Bold Pivot to Rare Lung Disease TherapyHigh

Opthea reports A$339.9M profit, pivots to rare lung disease treatment with OPT-302

2 Mar 2026 ·Appendix 4D Half-year report ·Unexpected ·85

Opthea Returns to ASX with Focused OPT-302 Program for Rare Lung Disease LAMMedium

Opthea reinstated to ASX, advances OPT-302 development for rare lung disease LAM

3 June 2026 ·Reinstatement and Development Program Update ·75

Opthea Reboots with OPT-302 to Target Rare Lung Disease LAMMedium

Opthea refocuses on rare lung disease LAM with OPT-302, targets ASX reinstatement in 2026

17 Dec 2025 ·Investor Update ·75

Opthea Advances OPT-302 Program Amid NASDAQ Exit and Strong Cash FlowMedium

Opthea reports Q2 FY26 cash inflow, NASDAQ delisting, and launches OPT-302 LAM program

30 Jan 2026 ·Quarterly Activity Report and Appendix 4C ·75

Notable Score 50–74

1

Opthea Cuts Costs, Settles Major Liability, and Eyes Strategic ResetMedium

Opthea simplifies operations, settles DFA liability, and advances strategic review with improved cash position

31 Oct 2025 ·Quarterly Activity Report and Appendix 4C ·70

Not Assessed Low Score, or missing data

0

No articles in this tier for the last 12 months.

Market Mentions 3 - appeared in market wrap coverage

These are market wrap articles where Opthea (ASX:OPT) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Market Wrap - Week 10 (2 Mar -> 6 Mar) 2026

Healthcare Wrap - Week 10 (2 Mar -> 6 Mar) 2026